Moderna's vaccine candidate - mRNA-1273 - is nearing the finish line in its push to enroll 30,000 individuals in a late-stage trial of a novel coronavirus va.
Supply deals have already been agreed for 5.303 billion doses, of which 2.728 billion (51 percent) have been bought by developed countries including the UK, US, Australia, Hong Kong & Macau, Japan, Switzerland and Israel, as well as the European Union
The companies would pledge to adhere to high scientific and ethical standards in the conduct of clinical studies and in their manufacturing processes, the Journal report said, citing the draft of a joint statement that is still being finalized.
The drug developer aims to recruit 30,000 healthy volunteers and said it expected enrollment in the late-stage study, which began in late-July, to be completed in September.
Significantly, the volunteers also produced higher levels of antibodies than those produced by patients who have recovered from COVID-19.
The potential agreement provides for an option for member states to buy an additional 80 million doses for a total of up to 160 million doses, the company said.
Moderna’s proposed price for the COVID-19 vaccine would apply to the United States and other high-income countries, according to a news report.
The trial is the first such late-stage study under the Trump administration's program to speed development of measures against the novel coronavirus, adding to hope that an effective vaccine will help end the pandemic.
With over 1.5 crore people across the globe having contracted the infection, the world is eagerly awaiting a vaccine that would bolster the global fight against COVID-19.
In the case of SARS-CoV-2, there is a spike protein, or the S-protein, which is the flag that the immune system needs to recognize as the signature of the virus.
The talks follow a deal reached in June by four EU states with AstraZeneca for the upfront purchase of 400 million doses of its potential COVID-19 vaccine, in principle available to all 27 EU nations.
Some of the disagreements have stoked concerns over the young biotech firm's relative inexperience and what the sources described as its lack of staff and expertise to oversee the most critical phase of human trials.
Soumya Swaminathan said that Moderna's COVID-19 vaccine candidate was ‘not far behind’ Astrazeneca's, among more than 200 candidates, 15 of which have entered clinical trials
Moderna said last week that the vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, offering a glimmer of hope for a vaccine among the most advanced in development.
In this edition of the Moneycontrol's Explained series, find out if the vaccine is worth the hype.
Overall, the study showed the vaccine was safe and all study participants produced antibodies against the virus.
Eight patients who were administered Moderna's vaccine were found to have antibody levels similar to those in blood samples of people who have recovered from COVID-19, according to early results from the study conducted by the National Institutes of Health.
Moderna had originally planned to sell 21.7 million shares for between $22 and $24 per share.